Piper Jaffray Upgrades DaVita To Overweight

According to Piper Jaffray, DaVita DVA is upgraded to Overweight. Piper Jaffray said that it is upgrading DVA to Overweight and raising the price target from $94 to $95. “While healthcare stocks have been pressured due to concerns about the debt ceiling, we believe dialysis reimbursement should be relatively stable over the next 12-18 months.” DaVita closed yesterday at $78.43.